Want to see PRPO full AI Analyst Report?
PRPO Stock Chart & Stats
$22.92
$0.07(0.31%)
At close: 4:00 PM EDT
$22.92
$0.07(0.31%)
Day’s Range― - ―
52-Week Range$13.80 - $33.63
Previous CloseN/A
Volume67.76K
Average Volume (3M)19.92K
Market Cap
$42.84M
Enterprise Value$45.47
Total Cash (Recent Filing)$2.60M
Total Debt (Recent Filing)$3.49M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding1,787,372
10 Day Avg. Volume16,445
30 Day Avg. Volume19,918
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)2.53
Price to Sales (P/S)1.53
P/FCF Ratio102.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.4
Revenue Forecast (FY)$80.26M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Pathology StrengthSustained top-line expansion, led by pathology, indicates durable demand for core diagnostic services and growing physician adoption. Year-over-year growth widens the addressable revenue base, supports future scale benefits, and underpins management's revenue-conversion thesis over coming quarters.
Improved Cash GenerationTransition to positive operating and free cash flow reduces reliance on external financing and improves operational resilience. Strong FCF growth versus recent years provides runway for commercialization investments and working-capital needs while lowering solvency risk in the medium term.
Lab Capacity And ScalabilityMeaningful spare lab capacity implies organic scaling with limited near-term capital spending, enabling margin expansion as volumes rise. Scalable fixed-cost base supports efficient incremental economics, assuming the company can convert pipeline to volume and reduce per-test unit costs as utilization grows.
Bears Say
Incomplete ProfitabilityDespite operational improvement, persistent net losses mean returns on equity remain below zero and the firm has not fully de‑risked execution. Continued sub‑break‑even periods could delay reinvestment or force capital raises, constraining long‑term return potential if profitability doesn't stabilize.
Reimbursement Risk (CMS Cut)Regulatory reimbursement changes directly compress revenue and gross profit for core tests; CMS adjustments can be permanent or recur across related codes. This creates structural revenue and margin pressure for a diagnostics provider reliant on payer rates rather than pricing power.
Onboarding & Conversion FrictionOperational frictions that delay onboarding lengthen time-to-revenue for new customers, making bookings less predictive and slowing scale benefits. Persistent integration or validation issues raise execution risk and can increase sales and implementation costs, reducing realized ROI on commercial investment.
Precipio News
PRPO FAQ
What was Precipio Inc’s price range in the past 12 months?
Precipio Inc lowest stock price was $13.80 and its highest was $33.63 in the past 12 months.
What is Precipio Inc’s market cap?
Precipio Inc’s market cap is $42.84M.
When is Precipio Inc’s upcoming earnings report date?
Precipio Inc’s upcoming earnings report date is Aug 17, 2026 which is in 6 days.
How were Precipio Inc’s earnings last quarter?
Precipio Inc released its earnings results on May 14, 2026. The company reported -$0.809 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Precipio Inc overvalued?
According to Wall Street analysts Precipio Inc’s price is currently Overvalued.
Does Precipio Inc pay dividends?
Precipio Inc does not currently pay dividends.
What is Precipio Inc’s EPS estimate?
Precipio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Precipio Inc have?
Precipio Inc has 1,787,372 shares outstanding.
What happened to Precipio Inc’s price movement after its last earnings report?
Precipio Inc reported an EPS of -$0.809 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.951%.
Which hedge fund is a major shareholder of Precipio Inc?
Currently, no hedge funds are holding shares in PRPO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precipio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
PRPO Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $100.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.97%
Trailing 12-Months
Company Description
Precipio Inc
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
PRPO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of strong underlying trends and short-term headwinds. Positives include >30% YoY revenue growth, a growing pathology business, a $10M annualized commercial pipeline and positive operating cash flow. Near-term negatives included an 8% CMS reimbursement cut causing a ~$0.5M write-down, a QoQ gross margin decline (47% to 40%), and an adjusted EBITDA decline to -$200k driven by timing and investment-related factors. Management framed most negatives as one-time or investment-driven and emphasized scalability, available lab capacity, and commercial momentum, with expectations for margin recovery as product revenue scales.View all PRPO earnings summariesTechnical Analysis
Ownership Overview
10.89% Insiders
2.28% Mutual Funds
1.91% Other Institutional Investors
81.82% Public Companies and
Individual Investors